Press Releases from Center for Genetic Engineering and Biotechnology (4 total)
Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with…
CIGB’s researchers defeat cancer once again
Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba,…
President of India visits CIGB today to reinforce bilateral trade and scientific …
Havana, June 22nd, 2018 - The 14th and current President of India, in office since July 25th 2017, Ram Nath Kovind (b. 1945) visited the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. President Ram Nath Kovind was received by the President of BioCubaFarma, Dr. Eduardo Martínez, and the General Director of the CIGB Dr. Eulogio Pimentel. This is a very important date in the agenda of Mr.…
Approval for commercialization of Heberprot-P® in Mexico
Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing…
